Alteration of antral and proximal colonic motility induced by chronic psychological stress involves central urocortin 3 and vasopressin in rats.
Because of the difficulties in developing suitable animal models, the pathogenesis of stress-induced functional gastrointestinal disorders is not well known. Here we applied the communication box technique to induce psychological stress in rats and then examined their gastrointestinal motility. We measured upper and lower gastrointestinal motility induced by acute and chronic psychological stress and examined the mRNA expression of various neuropeptides in the hypothalamus. Chronic psychological stress disrupted the fasted motility in the antrum and accelerated motility in the proximal colon. mRNA expression of AVP, oxytocin, and urocortin 3 was increased by chronic psychological stress. Intracerebroventricular (ICV) injection of urocortin 3 disrupted the fasted motility in the antrum, while ICV injection of Ucn3 antiserum prevented alteration in antral motility induced by chronic psychological stress. ICV injection of AVP accelerated colonic motility, while ICV injection of SSR 149415, a selective AVP V1b receptor antagonist, prevented alteration in proximal colonic motility induced by chronic psychological stress. Oxytocin and its receptor antagonist L 371257 had no effect on colonic motility in either the normal or chronic psychological stress model. These results suggest that chronic psychological stress induced by the communication box technique might disrupt fasted motility in the antrum via urocortin 3 pathways and accelerates proximal colonic motility via the AVP V1b receptor in the brain.
Department of Anatomy, Sapporo Medical University School of Medicine, Japan.
Koji
K
Ataka
Kanna
K
Nagaishi
Akihiro
A
Asakawa
Akio
A
Inui
Mineko
M
Fujimiya
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*; D003106:Colon / Q000294:innervation*; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D004386:Duodenum / Q000294:innervation; D005215:Fasting; D005767:Gastrointestinal Diseases / Q000209:etiology* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D005769:Gastrointestinal Motility / Q000187:drug effects; D006727:Hormone Antagonists / Q000008:administration & dosage; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D007106:Immune Sera / Q000008:administration & dosage; D007211:Indoles / Q000008:administration & dosage; D007276:Injections, Intraventricular; D008297:Male; D008365:Manometry; D010121:Oxytocin / Q000008:administration & dosage / Q000378:metabolism; D011312:Pressure; D011706:Pyloric Antrum / Q000294:innervation*; D011759:Pyrrolidines / Q000008:administration & dosage; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D060888:Real-Time Polymerase Chain Reaction; D017483:Receptors, Vasopressin / Q000378:metabolism; D013315:Stress, Psychological / Q000150:complications* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D013997:Time Factors; D015854:Up-Regulation; D054832:Urocortins / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*
C456029:1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide; D065092:Antidiuretic Hormone Receptor Antagonists; D006727:Hormone Antagonists; D007106:Immune Sera; D007211:Indoles; D011759:Pyrrolidines; D012333:RNA, Messenger; D017483:Receptors, Vasopressin; D054832:Urocortins; C514216:urocortin 3, rat; D001127:Arginine Vasopressin; D010121:Oxytocin; D003346:Corticotropin-Releasing Hormone